Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Shares of Regeneron Pharmaceuticals, Inc.REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%.. The stock has underperformed the sector and the S&P 500 ...

REGN stock fell 25.8% from a high of $738.84 on 8 April 2022 to $548.35 on 14 June 2022, vs. a peak-to-trough decline of 25.4% for the S&P 500 The stock fully recovered to its pre-Crisis peak by 4 ...

Regeneron’s financial performance has been mixed in recent quarters: The company reported both top and bottom line misses in its most recent earnings report. EPS estimates for 2025 have been ...

Regeneron just posted another impressive quarter for earnings (+16% YoY) and revenues (+17% YoY). Growth is set to slow after a one-time boost from its COVID antibody cocktail last year and an ...

Regeneron Pharmaceuticals stock surged on strong Q2 results and pipeline developments. Read this article to know if REGN can deliver more growth.

Regeneron isn't concerned, as the decision wasn't a result of any issues relating to the drug's safety or efficacy. Investor Alert: Our 10 best stocks to buy right now › NASDAQ: REGN ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 1.4% over the past week. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

This was the stock's second consecutive day of losses.

Shares of Regeneron REGN have gained 10.3% year to date against the industry’s decline of 14.8%. Regeneron managed to reverse its decline trajectory with the recent FDA approval of a higher dose ...